Tom Frohlich
Known title: Chief Executive OfficerCIK: 0001823925
Tom Frohlich's purchase track record
Tom Frohlich has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/16/2025 | JBIO | $44K | +0.2% | +45.7% | +13.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| JBIO | ▲ Buy | Grant | 78,750 | $0 | 2/12/2026 | View on chart |
| JBIO | ▲ Buy | Open Market | 6,000 | $44K | 5/16/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Jade Biosciences Schedules Conference Participation
Jade Biosciences has announced its participation in upcoming industry conferences. Such events typically provide opportunities for company leadership to engage with institutional investors and discuss business developments. The stock currently trades within its 52-week range, with analysts maintaining price targets significantly above current levels.
Jade Biosciences Schedules Conference Participation. Jade Biosciences has announced its participation in upcoming industry conferences. Such events typically provide opportunities for company leadership to engage with institutional investors and discuss business developments. The stock currently trades within its 52-week range, with analysts maintaining price targets significantly above current levels.